Market closed

Recursion Pharmaceuticals/$RXRX

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Recursion Pharmaceuticals

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Ticker

$RXRX
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Salt Lake City, United States

Employees

500
Website
www.recursion.com

RXRX Metrics

BasicAdvanced
$1.9B
-
-$1.54
0.80
-

$1.9B

0.8

$15.74

$5.60

16M

4.355

3.948

14.14

17.276

-398.03%

-36.40%

-78.49%

25.397

3.68

4.4

-4.932

37.64%

4.30%

84.75%

-2.64%

What the Analysts think about RXRX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Recursion Pharmaceuticals stock.

RXRX Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RXRX Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

RXRX News

AllArticlesVideos
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

GlobeNewsWire·1 week ago
Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

GlobeNewsWire·1 week ago
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RXRX

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Recursion Pharmaceuticals stock?

Recursion Pharmaceuticals (RXRX) has a market cap of $1.9B as of January 15, 2025.

What is the P/E ratio for Recursion Pharmaceuticals stock?

The price to earnings (P/E) ratio for Recursion Pharmaceuticals (RXRX) stock is 0 as of January 15, 2025.

Does Recursion Pharmaceuticals stock pay dividends?

No, Recursion Pharmaceuticals (RXRX) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Recursion Pharmaceuticals dividend payment date?

Recursion Pharmaceuticals (RXRX) stock does not pay dividends to its shareholders.

What is the beta indicator for Recursion Pharmaceuticals?

Recursion Pharmaceuticals (RXRX) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.